Targeting Drp1 activity by genetic approach or pharmacologic inhibitors attenuates growth of stem-like tumors and lead to good prognosis [74], thus, Drp1 serves as a potential target for cancer treatment. The gene discussed is DNM1L; the disease is cancer.